Cannabis Licensing Update: Week of September 21, 2026

Quick answer: Nebraska’s medical cannabis manufacturer application window has not closed — it was extended a third time, to December 14, 2026, though the Medical Cannabis Commission’s site still shows the outdated September 14 date, so confirm directly with MCC. Program rules remain unfinished, with an October 15, 2026 public hearing and final regulations not expected until 2027. The window is live now regardless of the rulemaking timeline.

Key takeaways:

• Nebraska’s manufacturer license application window, originally set to close Aug. 17 then Sept. 14, has been extended a third time to December 14, 2026; as of the Commission’s September 14, 2026 meeting, 10 manufacturer applications had been submitted so far.
• North Carolina’s Advisory Council on Cannabis subcommittee floated a three-tier model with private cultivation/manufacturing, an undecided distribution tier, and state-controlled retail, with final recommendations due to Gov. Josh Stein by December 31, 2026.
• North Dakota proposed medical cannabis certification fee increases of 47–150% — processor-only $20,000 → $50,000, production-only $40,000 → $70,000, dispensary $60,000 → $90,000, full manufacturing $75,000 → $110,000 — proposed effective November 1, 2026.
• Massachusetts’ CCC kicked off a regulatory overhaul September 16–17, 2026 that proposes a standalone medical dispensary license, but with a final vote targeted for March 2027, no applications could realistically open before spring/summer 2027 at the earliest.

Why this week matters

This week’s updates share a theme that trips up a lot of operators: headlines about rulemaking get read as headlines about licensing, and the two are not the same thing. Nebraska is the clearest example — the coverage is all about unfinished regulations and a 2027 timeline, while an actual manufacturer application window sits open through December 14, 2026. Missing that distinction means missing a live filing opportunity.

The other four states are about positioning rather than filing. North Carolina is debating a licensing structure that does not exist yet, Pennsylvania is escalating pressure on a bill that has not moved since July 2025, North Dakota is raising the cost of entry and renewal, and Massachusetts is drafting a genuinely new license type that nobody can apply for yet. Each one changes what a serious applicant should be doing right now — even where there is nothing to submit.

Is Nebraska’s medical cannabis manufacturer application window still open?

Yes. The window has NOT closed: it has been extended a third time. Originally set to close Aug. 17 and then Sept. 14, the manufacturer license application window now runs through December 14, 2026, per CBA’s own prior reporting in our Week of September 14 update.

• The Commission’s official site has not yet been updated to reflect this and still displays the outdated Sept. 14 deadline — recommend confirming directly with MCC before relying on the Dec. 14 date. See the Nebraska Medical Cannabis Commission — How to Apply page.
• As of the Commission’s September 14, 2026 meeting, 10 manufacturer applications had been submitted so far — an in-progress count, not a final closed tally.
• The dispensary license application window remains not yet open, pending further legislative/regulatory action.

As our consultant note puts it: this remains a live, open application opportunity — don’t let the confusing rules headlines suggest otherwise. More background on the program is in our Nebraska cannabis update.

Should Nebraska applicants wait for final program rules?

No — but they should apply with eyes open. Program rules are not yet final, and the October 15 hearing is a step in that still-open rulemaking process, which is not expected to be complete until 2027.

• Proposed rule changes include a new fee structure: manufacturer license fee, dispensary fee, application fee, and seed-to-sale tracking fee. See the Nebraska Medical Cannabis Commission — Rules & Regulations page.
• A public hearing is set for October 15, 2026, with commission review expected Oct. 19 or Nov. 16, 2026.
• Per Nebraska Public Media, Sept. 14, 2026, updated regulations for the program are not expected to be final until 2027.
• Separately, the Nebraska Supreme Court dismissed a federal-preemption lawsuit against the program for lack of standing (September 11, 2026, per Nebraska Examiner), reducing a legal-risk overhang for applicants — noted as background context, not this week’s news.

Manufacturer applicants still have a real window through Dec. 14 — that opportunity is live regardless of the rulemaking timeline. But applicants should go in knowing the rules they’ll ultimately operate under are still being finalized, with full adoption not expected until 2027. Dispensary licensing is still not open, and investors should continue to treat that as a later-stage opportunity.

What licensing model is North Carolina’s advisory council considering?

The NC Advisory Council on Cannabis’s Market and Regulatory Subcommittee discussed a three-tier framework blending North Carolina’s alcohol-control (ABC) system with elements of a government-run retail model. The subcommittee met September 18, 2026 and proposed:

• Private, licensed cultivation and manufacturing — including a new “Craft Farm Cannabis License” for small growers.
• An undecided distribution model: private wholesalers vs. a state-run warehouse vs. a hybrid.
• State-controlled retail via a new or existing agency.
• Final recommendations due to Gov. Josh Stein by December 31, 2026. Reporting via The Marijuana Herald; council background via the NC Advisory Council on Cannabis.

There is no license to apply for yet, but the framework being floated matters a great deal for future market entry. A state-controlled retail tier (versus private retail) would be a significant departure from most state models and would reshape how investors think about a future NC entry. Clients interested in North Carolina should watch for the December recommendations, which will likely shape enabling legislation in the 2027 session. Track the market in our North Carolina cannabis policy update.

How much are North Dakota’s medical cannabis certification fees going up?

The state Department of Health and Human Services proposed sharply higher certification fees for compassion center license categories, with a proposed effective date of November 1, 2026:

• Processor-only facility: $20,000 → $50,000 (+150%)
• Production-only facility: $40,000 → $70,000 (+75%)
• Dispensary: $60,000 → $90,000 (+50%)
• Full manufacturing facility: $75,000 → $110,000 (+47%)

The current codified fee table (NDAC 33-44-01-07.3) still reflects the lower, pre-increase amounts, consistent with this being a pending change — see the ND Legislature current fee schedule (33-44-01) and the report from The Marijuana Herald.

Existing and prospective ND licensees should budget for materially higher certification costs. A 47–150% fee jump raises the capital bar for market entry and renewal, especially for smaller operators. Clients evaluating North Dakota should model the higher fees into their financial projections now, ahead of the Nov. 1 effective date.

Does Pennsylvania’s September 25 hearing move SB 120 forward?

Not by itself. Sens. Nick Miller (chair) and Sharif Street announced a Senate Democratic Policy Committee hearing on adult-use cannabis legalization on September 21, 2026. The hearing, titled “Adult-Use Cannabis: Criminal Justice, Safety & Economic Impacts,” is set for September 25, 2026 in Philadelphia.

• The hearing is tied to Senate Bill 120 (Street/Laughlin, bipartisan), which has been stuck in the Senate Law & Justice Committee since July 2025.
• Every Senate Democrat has signed a discharge resolution to force a floor vote, though no vote has occurred yet.
• Coverage via The Marijuana Herald and Marijuana Moment.

Pennsylvania remains the biggest “watch and wait” market on CBA’s Key States list. A hearing alone doesn’t move SB 120 out of committee, but a unanimous Democratic discharge push is a real escalation. Clients positioning for eventual PA adult-use licensing should treat this as a signal to keep preparation moving, not as confirmation that legalization is imminent. See our Pennsylvania adult-use cannabis SB 120 breakdown.

Is Massachusetts’ proposed standalone medical dispensary license an opportunity today?

Not today — there is no application window and no DEA tie-in yet. The CCC’s newly restructured 3-member commission launched working groups to draft new regulations across several major topic areas, with a kickoff on September 16–17, 2026 confirmed via the CCC’s own press release and corroborated by The Marijuana Herald.

Key licensing-relevant proposals include:

• Creating a standalone medical dispensary license, ending the vertical-integration requirement for medical operators.
• Allowing license transfers from adult-use to medical establishments.
• Eliminating patient residency requirements.
• Considering statewide retail license caps.

For new and prospective licensees, the standalone medical dispensary concept is a genuinely new license type on paper, but neither the CCC’s release nor trade coverage specifies whether it will be open to brand-new entrants or only existing licensees converting or adding licenses — and no application-opening date exists yet. Given the drafting timeline (commissioner vote on draft language Dec. 2026 → public comment/hearings early 2027 → final vote March 2027), realistically no applications could open before spring/summer 2027 at the earliest.

Separate market-entry context: the CCC imposed a 120-day freeze on new cultivation license applications starting June 16, 2026 (oversupply concerns), while doubling adult-use retail license caps from 3 to 6 per operator; social equity and economic-empowerment microbusiness applicants were exempted from the cultivation freeze, per MJBizDaily.

On the DEA/federal angle: no connection was found between this CCC overhaul and DEA registration or federal rescheduling — that is a separate, parallel federal compliance track. State-licensed medical marijuana products moved to Schedule III effective April 23, 2026, which triggered a separate DEA business-registration process for state-licensed medical operators (Massachusetts MSO MariMed confirmed submitting its DEA registration applications June 25, 2026) — unrelated to the CCC’s current rulemaking effort.

A real new license type is on the table, but it’s 2027-or-later news, not an application opportunity today. Clients eyeing a Massachusetts medical entry should note the standalone dispensary license concept and start preparing, but should not expect to file anything before spring/summer 2027. Existing cultivation licensees should be aware of the freeze and expanded retail caps in the meantime; no DEA-registration action is required or implied by this particular rulemaking. More context in our Massachusetts cannabis program overview.

Frequently Asked Questions

Has Nebraska’s medical cannabis manufacturer application window closed?

No. The window has not closed — it has been extended a third time, from Aug. 17 to Sept. 14 and now to December 14, 2026. The Commission’s official site has not yet been updated and still displays the outdated Sept. 14 deadline.

When will Nebraska’s medical cannabis program rules be final?

Program rules are not yet final. A public hearing on proposed rule changes is set for October 15, 2026, with commission review expected Oct. 19 or Nov. 16, 2026. Per Nebraska Public Media, updated regulations for the program are not expected to be final until 2027. The manufacturer application opportunity is live regardless of that rulemaking timeline.

How much will North Dakota’s medical cannabis business certification fees increase?

The proposed increases, effective November 1, 2026, are: processor-only facility $20,000 to $50,000 (+150%); production-only facility $40,000 to $70,000 (+75%); dispensary $60,000 to $90,000 (+50%); and full manufacturing facility $75,000 to $110,000 (+47%). The current codified fee table (NDAC 33-44-01-07.3) still reflects the lower, pre-increase amounts.

Can I apply for Massachusetts’ new standalone medical dispensary license now?

No. No application-opening date exists yet, and it is not specified whether the license will be open to brand-new entrants or only to existing licensees converting or adding licenses. Given the drafting timeline — commissioner vote on draft language Dec. 2026, public comment and hearings early 2027, final vote March 2027 — applications realistically could not open before spring/summer 2027 at the earliest.

How CBA Can Help

CBA tracks these licensing windows, rulemaking calendars and fee changes week by week so clients know the difference between a live application opportunity and a headline about rules that won’t be final until 2027. We help manufacturer applicants move on Nebraska’s open window before December 14, 2026, and help clients evaluating North Dakota, North Carolina, Pennsylvania and Massachusetts model higher fees and pre-licensing frameworks into their market-entry planning.

Contact The Cannabis Business Advisors (CBA) to review your state-by-state filing calendar before the next deadline.